Mesoblast Financial Statements
NASDAQ: MESOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mesoblast revenue and earnings
In fiscal 2025, Mesoblast generated $17.2 million in revenue, up 191.4% from fiscal 2024. Mesoblast reported a net loss of $102.1 million, compared with a loss of $88.0 million a year earlier. Gross margin was 70.2% (down from 100.0%).
Diluted earnings per share came in at -$0.0846. Over the last 5 fiscal years, MESO's revenue has grown at a -11.8% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Mesoblast income statement (annual)
| Fiscal year (USD) | FY 20252025-06-30 | FY 20242024-06-30 | FY 20232023-06-30 | FY 20222022-06-30 | FY 20212021-06-30 | FY 20202020-06-30 | FY 20192019-06-30 | FY 20182018-06-30 | FY 20172017-06-30 | FY 20162016-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.20M | 5.90M | 7.50M | 10.21M | 7.43M | 32.16M | 16.72M | 17.34M | 2.41M | 42.55M |
| Revenue growth (YoY) | +191.39% | -21.32% | -26.54% | +37.36% | -76.88% | +92.30% | -3.57% | +618.95% | -94.33% | — |
| Cost of Revenue | 5.13M | 0 | 0 | — | — | — | — | — | — | — |
| Gross Profit | 12.07M | 5.90M | 7.50M | — | — | — | — | — | — | — |
| Research & Development | 34.81M | 39.72M | 52.82M | 32.81M | 53.01M | 56.19M | 59.81M | 65.93M | 58.91M | 50.01M |
| Selling, General & Admin | 39.31M | 24.98M | 27.48M | — | — | — | — | — | — | — |
| Interest Expense | 22.97M | 23.01M | 20.12M | 17.29M | 10.71M | 14.11M | 12.08M | 1.83M | — | — |
| Pretax Income | -101.81M | -88.15M | -82.10M | -91.59M | -99.63M | -87.36M | -98.75M | -65.98M | -90.22M | -90.82M |
| Income Tax | 330.00K | -191.00K | -212.00K | -239.00K | -819.00K | -9.41M | -8.96M | -30.69M | -13.40M | -86.69M |
| Net Income | -102.14M | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M | -89.80M | -35.29M | -76.81M | -4.13M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.0846 | -0.0891 | -0.1053 | -0.1338 | -0.1633 | -0.1474 | -0.1816 | -0.0758 | -0.1925 | -0.0113 |
| EPS (Diluted) | -0.0846 | -0.0891 | -0.1053 | -0.1338 | -0.1633 | -0.1474 | -0.1816 | -0.0758 | -0.1925 | -0.0113 |
| Shares Outstanding (Basic) | 1.21B | 986.70M | 777.72M | 682.86M | 605.06M | 528.82M | 494.38M | 465.69M | 399.04M | 364.21M |
| Shares Outstanding (Diluted) | 1.21B | 986.70M | 777.72M | 682.86M | 605.06M | 528.82M | 494.38M | 465.69M | 399.04M | 364.21M |
| Gross Margin | 70.17% | 100.00% | 100.00% | — | — | — | — | — | — | — |
| Net Margin | -593.92% | -1490.27% | -1091.71% | -894.59% | -1329.18% | -242.38% | -537.01% | -203.51% | -3184.70% | -9.70% |
This table shows 10 annual periods of Mesoblast's income statement, from FY 2025 back to FY 2016, across 15 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MESO's reporting calendar. What is a income statement?